Politics / Law

Commission greenlights import of GM maize MIR604

01.12.2009

With the authorisation on November 30 of the genetically modified (GM) maize MIR604, the European Commission has fulfilled the final requests made by US farming lobby groups and their European counterparts regarding the maize. MIR604 is authorised for the next ten years for food and feed uses, and for import and processing. This takes the number of GM maize lines approved by the European Commission to four within the last month. The US Grain Council, a farming lobby organisation, has been putting increasing pressure on the European Commission to wave through the four GM maize lines 59122xNK603 from Pioneer Hi-Bred, Monsanto's Mon88017 and 99034, and Syngenta's MIR604. Traces of these four lines have been found in soybean and soymeal shipments from the US, and have therefore been turned back at European ports (more…). The European grain and oilseeds trade association Coceral thus joined ranks with their US counterparts to lobby for the lifting of the zero tolerance policy oncerning traces of GM plants. The Commission has now solved the problem by authorising the import and processing of all GM maize lines in question. Mon88017 and 89034, and 59122xNK603, were already given a green light on October 30. The whole process has been relatively quick for European standards - all four GM plants had been awaiting authorisation for some years, with some queuing for approval since 2005. As with the other maize lines, the MIR604 maize received a positive safety assessment from the European Food Safety Authority (EFSA), and underwent the full authorisation procedure set out in EU legislation. Because the member states failed to return a qualified majority decision for or against this authorisation in the Standing Committee on the Food Chain and Animal Health (SCoFCAH), and then failed again to do so in the Council, the dossier was sent back to the Commission for adoption. Any products made using MIR604 maize will be subject to the EU's labelling and traceability regulations.

Politics / Law

23.03.2012

Brussels/Strasbourg – Health claims are set to be drastically limited in the EU. On Wednesday 21 March the Environment Committee of the European Parliament confirmed a proposal of the European Commission to prohibit 1,600 health...

Politics / Law

15.03.2012

Parma/Stockholm – Foodborne bacteria such as Salmonella and Campylobacter are becoming more and more resistant to antimicrobial drugs, according to a joint report published by the European food watchdog EFSA and the European...

BioFunding

09.03.2012

In mid-February, scientists and entrepreneurs from nine EU countries met at the Center for Genomic Regulation (CRG) in Barcelona to launch the 4DCellFate project. Positioned within the FP7 Programme, the consortium will receive...

BioFunding

09.03.2012

Brussels – The EU’s Innovative Medicines Initiative (IMI) will establish the European Lead Factory, an EU-wide public-private partnership aiming to facilitate drug discovery efforts. The Lead Factory will comprise a...

Editorial

07.03.2012

T    he societal and economic challenges facing Europe and the world are complex and interconnected. The Bioeconomy Strategy and Action Plan “Innovating for Sustainable Growth: a Bioeconomy for Europe”, which was adopted by the...

Tech Review

07.03.2012

Intellectual Property (IP) is without question one of the most vital aspects of any bio­tech venture, a key and undisputed factor for success. However, most bio­tech companies are still incapable of unlocking the value of their...

Clinical Trial

07.03.2012

Schlieren – Swiss Cytos Biotechnology Ltd. has been authorised to restructure a convertible bond by Canton of Zurich authorities. The company does not have enough cash to pay it back. Negotiations with bond holders failed in a...

Clinical Trial

06.03.2012

Munich – German 4SC AG jumped 39% to €2.05/share after oncology drug candidate resminostat met the primary endpoint of at least a 20% progression-free survival rate in a Phase II trial to treat patients with hepatocellular...

Editorial

06.03.2012

The start of 2012 witnessed the tides turning in favour of small and mid-cap names in the European Life Sciences sector. Major global biotechnology indices like the NBI, BTK, and BIOTK are up over 15% year to date. The pace of...

Displaying results 1 to 10 out of 1982

1-10 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/news/messages-archive/archive/article/commission-greenlights-import-of-gm-maize-mir604.html

Events

All Events

Stock list

All quotes

TOP

  • 4SC1.23 EUR6.03%
  • VITA 343.96 EUR4.49%
  • WILEX2.36 EUR4.42%

FLOP

  • CYTOS0.26 CHF-3.70%
  • MOLOGEN7.10 EUR-2.74%
  • ADDEX4.00 CHF-1.72%

TOP

  • SANTHERA82.95 CHF19.7%
  • MAGFORCE6.50 EUR10.2%
  • LONZA101.10 CHF7.1%

FLOP

  • MOLOGEN7.10 EUR-24.5%
  • WILEX2.36 EUR-24.4%
  • 4SC1.23 EUR-15.2%

TOP

  • SANTHERA82.95 CHF3850.0%
  • CO.DON2.50 EUR228.9%
  • PAION2.48 EUR198.8%

FLOP

  • CYTOS0.26 CHF-93.5%
  • MEDIGENE4.65 EUR-67.7%
  • MERCK KGAA64.40 EUR-45.7%

No liability assumed, Date: 21.08.2014


Current issue

All issues

Product of the week

Products